Prelude Therapeutics (PRLD) Liabilities and Shareholders Equity (2019 - 2026)

Prelude Therapeutics has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $119.6 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $119.6 million, down 15.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $470.6 million (down 36.25% YoY), and the FY2025 annual result was $141.3 million, down 19.49% from the prior year.
• Liabilities and Shareholders Equity came in at $119.6 million for Q1 2026 at Prelude Therapeutics, down from $141.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $280.7 million in Q1 2022 to a low of $94.8 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $220.5 million (2022), against an average of $204.3 million.
• Across the five-year window, Liabilities and Shareholders Equity advanced 25.93% in 2023 and sank 51.95% in 2025, its largest moves.
• Prelude Therapeutics' Liabilities and Shareholders Equity stood at $220.5 million in 2022, then gained by 25.93% to $277.7 million in 2023, then slumped by 36.79% to $175.5 million in 2024, then dropped by 19.49% to $141.3 million in 2025, then declined by 15.34% to $119.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $119.6 million (Q1 2026), $141.3 million (Q4 2025), and $94.8 million (Q3 2025), per Business Quant data.